HAV

HAV Full Name

HAV

HAV Introduction

Hepatitis A virus (HAV) is a small, positive-sense single-stranded RNA virus belonging to the genus Hepatovirus in the family Picornaviridae. It is the causative agent of Hepatitis A, an acute liver infection that remains a significant public health concern worldwide, particularly in regions with limited sanitation and safe water supplies. Unlike chronic viral hepatitis caused by Hepatitis B virus or Hepatitis C virus, HAV infection is typically self-limiting, but it can still lead to severe acute hepatitis and, in rare cases, fulminant liver failure. Researchers studying HAV frequently focus on viral RNA replication machinery, viral capsid proteins, and host factors that facilitate viral entry and replication in hepatocytes. Understanding these targets is crucial because clinicians and researchers still face the challenge that no widely approved direct-acting antiviral drugs specifically targeting HAV are available, leaving prevention and supportive care as the primary management strategies.

At the molecular level, HAV replication relies on a viral RNA-dependent RNA polymerase and several non-structural proteins that coordinate viral genome amplification in infected liver cells. Experimental antiviral strategies often target this replication process. For example, the nucleoside analog Favipiravir (T-705) has demonstrated the ability to inhibit HAV replication by inducing lethal mutagenesis during viral RNA synthesis. Studies in human hepatocyte cell lines such as Huh7 and PLC/PRF/5 have shown that treatment with Favipiravir significantly increases mutation frequency within the HAV genome, ultimately rendering viral particles non-infectious. Compared with another antiviral nucleoside analog, Ribavirin, Favipiravir produces a stronger mutagenic effect on HAV replication intermediates. These findings highlight viral polymerase activity and genome stability as promising therapeutic targets for antiviral development, particularly for severe HAV infections where supportive therapy alone may be insufficient.

Recent advances in HAV biology have also revealed unique virus–host interactions that influence transmission, immune evasion, and disease surveillance. One notable discovery is the existence of quasi-enveloped HAV particles, often referred to as eHAV, which are released from infected hepatocytes through host membrane-derived vesicles via the ESCRT pathway involving proteins such as VPS4B and ALIX. This quasi-enveloped form helps the virus evade neutralizing antibodies during circulation in the bloodstream. Once secreted into bile and exposed to bile salts, the membrane is removed, producing a stable non-enveloped virion that spreads through the fecal–oral route. Beyond molecular research, public health studies have also explored wastewater-based monitoring to detect HAV circulation in communities and evaluate the effectiveness of vaccination strategies. In particular, vaccination programs have proven highly effective in high-risk populations, highlighting how integrating molecular virology, environmental surveillance, and immunization strategies can significantly improve prevention and control of HAV outbreaks.

Alternate Names for HAV

HAV; Hepatitis A; Hepatitis A Virus; HAV VP1

• Reagents for HAV Serology Testing and Vaccine Research
• Reagents for HAV Serology Testing and Vaccine Research
• Reagents for HAV Serology Testing and Vaccine Research
• Reagents for HAV Serology Testing and Vaccine Research
• Humanized Control Antibodies for Infectious Disease Diagnostics
• Humanized Control Antibodies for Infectious Disease Diagnostics

• 1.Das A, et al.; Cell entry and release of quasi-enveloped human hepatitis viruses. Nat Rev Microbiol. 2023, 21(9):573-589.
  2.Sasaki-Tanaka R, et al.; Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes. Int J Mol Sci. 2022, 23(5):2631.